Chargement en cours...
Capecitabine in combination with mitomycin C in patients with gastrointestinal cancer: results of an extended multicentre phase-I trial
The aim of this study was to determine the dose-limiting toxicity (DLT) and establish the recommended dose for mitomycin C added every 3 weeks to the standard combination dose of capecitabine. Cohorts of at least three patients with pretreated gastrointestinal carcinoma received capecitabine 1000 mg...
Enregistré dans:
| Auteurs principaux: | , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Nature Publishing Group
2004
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2409860/ https://ncbi.nlm.nih.gov/pubmed/15238990 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6602025 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|